1
|
Wada K, Takaguri A, Kaneda K, Mizukami M, Suzuki Y, Yamashita H. Rational design and structure-activity relationship studies reveal new esterified C 20-diterpenoid alkaloid analogues active against MCF-7 human breast cancer cells. J Nat Med 2023; 77:276-283. [PMID: 36477683 DOI: 10.1007/s11418-022-01667-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 11/24/2022] [Indexed: 12/12/2022]
Abstract
Although various diterpenoid alkaloids have been evaluated recently for antiproliferative activity against human tumor cell lines, little information is available regarding the antiproliferative effects of C20-diterpenoid alkaloids against MCF-7 cells. Six new diterpenoid alkaloid derivatives (13, 14, 22, 23, 25, 26) were prepared by C-11 and 15 esterification of kobusine (6). The natural parent alkaloid 6 and all synthesized derivatives (7 - 27, 12a, 15a, 15b, 18a, 18b) were evaluated for antiproliferative activity against MCF-7 cells. The structure-based design strategy resulted in an initial lead derivative, 11,15-dibenzoylkobusine (7; IC50 8.6 µM). Subsequent synthesized 11,15-diacylkobusine derivatives (9, 16, 20, 21, 23, 25, and 26) showed substantially increased suppressive effects against the MCF-7 cell line (IC50 2.3-4.4 µM). In contrast, parent alkaloid 6, two 11-acylkobusine derivatives (15a, 18a), and two 15-acylkobusine derivatives (15b, 18b) showed no effect. 11,15-Diacylation appears to be critical for producing antiproliferative activity in this alkaloid class and could introduce a new avenue in overcoming breast cancer cell proliferation using natural product derivatives. In a preliminary mechanism of action study, representative derivatives (5, 8, 9, and 17) decreased cyclin D1 mRNA expression.
Collapse
Affiliation(s)
- Koji Wada
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan.
| | - Akira Takaguri
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan
- Creation Research Institute of Life Science in KITA-No-DAICHI, Hokkaido University of Science, Sapporo, Hokkaido, Japan
| | - Kyosuke Kaneda
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan
- Creation Research Institute of Life Science in KITA-No-DAICHI, Hokkaido University of Science, Sapporo, Hokkaido, Japan
| | - Megumi Mizukami
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan
| | - Yuji Suzuki
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan
| | - Hiroshi Yamashita
- Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Choume, Teine-Ku, Sapporo, 006-8585, Japan
| |
Collapse
|